Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
暂无分享,去创建一个
Dirk Schadendorf | Reinhard Dummer | Paolo A Ascierto | D. Schadendorf | C. Horak | P. Ascierto | R. Dummer | J. Wolchok | J. Larkin | F. Hodi | M. Smylie | L. Bastholt | M. Sznol | M. Callahan | M. Postow | P. Rutkowski | J. Grob | V. Chiarion-Sileni | G. McArthur | R. Gonzalez | G. Long | J. Haanen | M. Maio | B. Dréno | M. Carlino | J. Wagstaff | C. Lao | K. Grossmann | A. Yang | P. Ferrucci | A. Hill | I. Márquez-Rodas | L. Rollin | Piotr Rutkowski | Georgina V Long | Grant A McArthur | Michele Maio | James Larkin | Rene Gonzalez | Jedd D Wolchok | Lars Bastholt | C Lance Cowey | C. L. Cowey | John B Haanen | Margaret K Callahan | Brigitte Dreno | John Wagstaff | F Stephen Hodi | Matteo S Carlino | Andrew Hill | Vanna Chiarion-Sileni | Christine Horak | Jean Jacques Grob | Christopher D Lao | Michael Smylie | Pier F Ferrucci | Ivan Marquez-Rodas | Michael A Postow | Kenneth Grossmann | Mario Sznol | Arvin Yang | Linda M Rollin | Jedd D. Wolchok | Michael A. Postow | C. Cowey
[1] D. Schadendorf,et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma , 2015, Journal of Translational Medicine.
[2] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[3] J. Wolchok,et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Michael A. Davies,et al. Pathways and therapeutic targets in melanoma , 2014, Oncotarget.
[5] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[6] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[7] D. Schadendorf,et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[9] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[10] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[11] J. Allison,et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.
[12] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[13] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[14] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[15] I. Mellinghoff. Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University Curriculum vitae and Bibliography , 2014 .
[16] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[17] J. Wolchok,et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[19] G. Linette,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[20] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.